Abstract:Current evidence suggests that progressive neurodegeneration in Alzheimer's disease (AD) may be catalyzed by the prion-like propagation of soluble toxic amyloid-beta oligomers (AβO) rather than plaque burden. Binding of Aβ monomers and/or fibrils by therapeutic antibodies has been associated with suboptimal efficacy and adverse events (e.g. ARIA-E) in clinical trials. These observations suggest that antibodies capable of specifically or selectively neutralizing toxic AβO are needed to achieve improved efficacy and safety. Computational algorithms were developed to identify epitope sequences and conformations likely to be exposed in toxic AβO but not on monomers or fibrils. The binding profile of monoclonal antibodies raised against predicted epitopes was assessed by surface plasmon resonance (SPR) analysis and immunohistochemistry (IHC). Inhibition of oligomer propagation was assessed by thioflavin-T fluorescence in vitro. Neutralization of AβO neurotoxicity by the antibodies was evaluated in cultures of primary neurons in vitro and in wild-type mice injected intracerebroventricularly with AβO in vivo. Screening of IgG clones raised against 5 distinct AβO epitopes yielded antibodies with the desired profile of selective binding to synthetic oligomers vs monomers, preferential binding to native soluble AβO in CSF and brain extracts of AD patients compared to controls by SPR, and lack of plaque reactivity by IHC on unfixed AD brain sections. Activity assays led to the identification of PMN310 as a lead antibody capable of blocking the propagation and neurotoxicity of AβO in vitro and protecting mice against the AβO-induced loss of short term memory formation in vivo. Computational modeling allowed for the identification and generation of monoclonal antibodies against AβO-specific epitopes. Antibody PMN310 was selected as a lead candidate on the basis of its ability to selectively target and neutralize AβO with no significant cross-reactivity to monomers or fibrils. These unique characteristics distinguish PMN310 from Aβ-reactive antibodies currently undergoing clinical trials, and are designed to address observed issues of efficacy and safety.

Investigating the Mechanisms of Antibody Binding to Alpha-Synuclein for the Treatment of Parkinson's Disease

Investigating the mechanisms of antibody binding to alpha-synuclein for the treatment of Parkinson’s Disease

A brain-shuttled antibody targeting alpha synuclein aggregates for the treatment of synucleinopathies

Rational Generation of Monoclonal Antibodies Selective for Pathogenic Forms of Alpha-Synuclein

Characterization of a Novel Monoclonal Antibody for Serine-129 Phosphorylated α-Synuclein: A Potential Application for Clinical and Basic Research

Randomized Phase I Trial of the α‐Synuclein Antibody Lu AF82422

Novel Naturally Occurring Autoantibodies Attenuate Α‐synuclein Pathology in a Mouse Model of Parkinson's Disease

Probing the molecular mechanisms of α-synuclein inhibitors unveils promising natural candidates through machine-learning QSAR, pharmacophore modeling, and molecular dynamics simulations

Chemoselective Bioconjugation of Amyloidogenic Protein Antigens to PEGylated Microspheres Enables Detection of α-Synuclein Autoantibodies in Human Plasma

Rational design of structure-based vaccines targeting misfolded alpha-synuclein conformers of Parkinson's disease and related disorders

A Single Chain Fragment Variant Binding Misfolded Alpha-Synuclein Exhibits Neuroprotective and Antigen-Specific Anti-Inflammatory Properties

Prediction of Inhibitors Against Alpha-Synuclein Fibrils Formed in Parkinson’s Disease

Development of Alpha-Synuclein protein model against therapeutic aspects of Parkinson’s disease

Quantitative systems pharmacology model of α-synuclein pathology in Parkinson's disease-like mouse for investigation of passive immunotherapy mechanisms

Discovery of Styrylaniline Derivatives As Novel Alpha-Synuclein Aggregates Ligands.

Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy

Selection of DNA aptamers that prevent the fibrillization of α-synuclein protein in cellular and mouse models

A dual target molecular magnetic resonance imaging probe for noninvasive profiling of pathologic alpha-synuclein and microgliosis in a mouse model of Parkinson's disease

Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial

alpha-Synuclein as a Diagnostic Marker and Therapeutic Target for Parkinson Disease

TARGETING OF TOXIC AMYLOID-BETA OLIGOMER SPECIES BY MONOCLONAL ANTIBODY PMN310: PRECISION DRUG DESIGN FOR ALZHEIMER’S DISEASE